Abdelrahim Maen, Esmail Abdullah, Abudayyeh Ala, Murakami Naoka, Victor David, Kodali Sudha, Cheah Yee Lee, Simon Caroline J, Noureddin Mazen, Connor Ashton, Saharia Ashish, Moore Linda W, Heyne Kirk, Kaseb Ahmed O, Gaber A Osama, Ghobrial Rafik Mark
Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77030, USA.
Cockrell Center of Advanced Therapeutics Phase I Program, Houston Methodist Research Institute, Houston, TX 77030, USA.
Cancers (Basel). 2023 Nov 9;15(22):5337. doi: 10.3390/cancers15225337.
Transplant oncology is an emerging concept of cancer treatment with a promising prospective outcome. The applications of oncology, transplant medicine, and surgery are the core of transplant oncology to improve patients' survival and quality of life. The main concept of transplant oncology is to radically cure cancer by removing the diseased organ and replacing it with a healthy one, aiming to improve the survival outcomes and quality of life of cancer patients. Subsequently, it seeks to expand the treatment options and research for hepatobiliary malignancies, which have seen significantly improved survival outcomes after the implementation of liver transplantation (LT). In the case of colorectal cancer (CRC) in the transplant setting, where the liver is the most common site of metastasis of patients who are considered to have unresectable disease, initial studies have shown improved survival for LT treatment compared to palliative therapy interventions. The indications of LT for hepatobiliary malignancies have been slowly expanded over the years beyond Milan criteria in a stepwise manner. However, the outcome improvements and overall patient survival are limited to the specifics of the setting and systematic intervention options. This review aims to illustrate the representative concepts and history of transplant oncology as an emerging discipline for the management of hepatobiliary malignancies, in addition to other emerging concepts, such as the uses of immunotherapy in a peri-transplant setting as well as the use of circulating tumor DNA (ctDNA) for surveillance post-transplantation.
移植肿瘤学是癌症治疗中一个新兴的概念,具有良好的预期结果。肿瘤学、移植医学和外科手术的应用是移植肿瘤学的核心,旨在提高患者的生存率和生活质量。移植肿瘤学的主要概念是通过切除患病器官并用健康器官取而代之来根治癌症,目的是改善癌症患者的生存结果和生活质量。随后,它试图扩大对肝胆恶性肿瘤的治疗选择和研究,在实施肝移植(LT)后,这些肿瘤的生存结果有了显著改善。在移植背景下的结直肠癌(CRC)病例中,肝脏是被认为患有不可切除疾病患者最常见的转移部位,初步研究表明,与姑息治疗干预相比,LT治疗的生存率有所提高。多年来,肝胆恶性肿瘤LT的适应症已逐步缓慢地扩展到米兰标准之外。然而,结果的改善和患者的总体生存仅限于特定的环境和系统干预选项。本综述旨在阐述移植肿瘤学作为肝胆恶性肿瘤管理新兴学科的代表性概念和历史,此外还包括其他新兴概念,如移植围手术期免疫疗法的应用以及移植后使用循环肿瘤DNA(ctDNA)进行监测。